52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Davita Inc Reports Q3 Earnings Per Share of $2.36 From Continuing Operations
Berkshire Hathaway stake in DaVita rises to 34.4%, share count unchanged
Davita Inc Reports Q2 Revenue Of $2.917 Bln
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
2000 16th St
Pamela M. Arway
Independent Chairman of the Board
Javier J. Rodriguez
Chief Executive Officer, Director
Chief Financial Officer, Treasurer
John D. Winstel
Chief Accounting Officer
James O. Hearty
Chief Compliance Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Federal Trade Commission said on Monday it was restoring its practice of requiring companies that previously pursued an anticompetitive deal to get prior approval for certain future transactions, even very small ones.
Dialysis provider DaVita and its former CEO Kent Thiry were indicted by a federal grand jury in Denver on charges they conspired with competitors not to hire each other's key employees, the U.S. Justice Department said on Thursday.
* DAVITA INC. ANNOUNCES PRICING OF $1.75 BILLION SENIOR NOTES OFFERING
* DAVITA INC. ANNOUNCES OFFERING OF $1.75 BILLION SENIOR NOTES
* Q1 ADJUSTED EARNINGS PER SHARE $1.83 FROM CONTINUING OPERATIONS
* DAVITA LAUNCHES VENTURE GROUP TO ACCELERATE ADVANCEMENTS IN KIDNEY CARE Source text for Eikon: Further company coverage:
* DAVITA INC - SCREENING EVERY PERSON WHO ENTERS A DAVITA CENTER FOR SYMPTOMS AND EXPOSURE TO COVID-19
* DAVITA KIDNEY CARE SAYS PLANS TO HIRE AT LEAST 15,000 NEW EMPLOYEES THROUGHOUT 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus.
* DAVITA KIDNEY CARE - ANNOUNCED IT IS GIVING U.S. EMPLOYEES, KNOWN AS TEAMMATES, AN EXTRA $100 EACH WEEK Source text for Eikon: Further company coverage:
Dialysis providers DaVita Inc and Fresenius Medical Care violated an anti-kickback law by contributing to a charity that helps kidney disease patients afford treatment that then steered business to them, a newly unsealed whistleblower lawsuit alleges.
UnitedHealth Group Inc won anti-trust approval to buy DaVita Inc's primary and urgent care unit for $4.3 billion, the Federal Trade Commission said on Wednesday.
UnitedHealth Group Inc won antitrust approval to buy DaVita Inc's primary and urgent care unit for $4.3 billion, the Federal Trade Commission said on Wednesday. (Reporting by Diane Bartz Editing by Leslie Adler)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.